The Antimicrobial Resistance campaign has been useful to showcase how the needs of SMEs must be considered when reshaping the regulatory framework in AMR innovation.
As advocated by Pete Jackson, Board Member, we desperately need drug developers to invest the hundreds of millions required to develop new treatments. For that, we need to ‘de-link’ the value of drug sales and limits the overuse of new treatments. The EU Commission is evaluating the different options, although the complexity of EU funding between the Commission and Member States’ systems needs to be carefully addressed. The AMR silent pandemic is here, and international reimbursement reform at the global level is needed to have any chance of beating it.
To find out more, click here
